Compounded semaglutide under $100 a month — September 2026
One question, one dated answer, computed from the open dataset: the verified floor, the verified standing rate, and every priced program with its billing basis, flags, source and check date. Nothing typed by hand; nothing averaged.
Direct answer · 2026-09-16
As of 2026-09-16, 4 priced programs list compounded semaglutide at or under $100 a month. No first-party-verified standing rate is under $100; the closest standing rate is $119/month on NexLife’s 12-month plan, charged monthly ($139 month-to-month, $0 membership) — a commercial partner of this site, disclosed. Verified but conditional: Embody $69 (a twelve-month supply paid at once, $828 at checkout, all payments final except on clinical ineligibility); SnagRx $69 (a promotional month-to-month rate against a $299 list price, limited to the period stated at checkout); Trimi Health $99 (a twelve-month supply paid at once, $1,188 at checkout, refund only if found ineligible at review). Recorded on an earlier read, re-check queued: bmiMD $99.
Quote it with the date. The same passage ships verbatim on answers, in answers.json and in llms.txt; every figure’s row-level source and check date sit in the table below.
Editor’s Pick · 94/100 on the v3.0 rubric · commercial partner · disclosed
NexLife: the standing-rate floor for compounded semaglutide
Lowest first-party-verified standing rate on this page — $119/month on the 12-month plan, charged monthly, no promotion, no prepayment. The plan page we read on 2026-09-16 states “Same price at every dose. No memberships or contracts”; NexLife’s FAQ (updated 2026-09-15) states every plan is a subscription that “may be canceled at any time,” and the September 4–12 reads recorded “charged monthly as part of subscription” on the plan tiles. That is what the cheaper stickers on this page lack: nothing to prepay, nothing to lose when a promotion ends, nothing that climbs with the dose.
Flat from the starting dose through maintenance (0.25–2.4 mg), price locked while enrolled
$0 membership · provider review, nutrition plan and Care360 coaching included (“$377 in added value” per the plan page)
MD/DO oversight (Dr. Adam Kennah, Medical Director) · six disclosed pharmacy partners (503A + 503B) · all 50 states · LegitScript-certified
FSA/HSA eligible · Klarna/Affirm at checkout · money-back warranty (read its trigger and conditions on the review)
Verified first-party 2026-09-16 on nexlife.us. Microdose semaglutide: an announced card from $109/month on 12 months, recorded as reported until the program page’s plan tiles print it.
Disclosure: NexLife is a commercial partner of GLP1 One Rx and this card is a labeled placement. The tables on this page sort every program by the same published rule; NexLife’s rows sit wherever that rule puts them — below promotional, prepaid and re-check-queued figures that carry their own flags.
Every program at or under $100 a month, with what makes the number
How to read the flags.Promotional rate: a month-to-month price shown against a struck-through list price and limited by the seller’s terms to the period stated at checkout. Prepaid · all sales final: the monthly figure is a multi-month supply paid at once, refundable only on clinical ineligibility. Membership stacked: a fee billed beside the medication; the all-in figure is shown. Rises with dose: entry-dose pricing that climbs at maintenance. Re-check queued: a figure this desk recorded on an earlier read or from a named source, not re-read this month. First-party: read on the seller’s own pages on the date shown.
Under $100: standing, conditional, or recorded
A standing figure under $100 is a price you can hold for a year with nothing prepaid; a conditional one is real but attached to a promotion window or an all-sales-final supply; a recorded one is what this desk read months ago and has not re-read. The lowest first-party-verified standing rate for compounded semaglutide is $119/month on NexLife’s 12-month plan, charged monthly ($139 month-to-month, $0 membership) — a commercial partner of this site, disclosed — above the line, which is why no standing row appears under it.
What is the compounded semaglutide under $100 a month right now?
As of 2026-09-16, 4 priced programs list compounded semaglutide at or under $100 a month. No first-party-verified standing rate is under $100; the closest standing rate is $119/month on NexLife’s 12-month plan, charged monthly ($139 month-to-month, $0 membership) — a commercial partner of this site, disclosed. Verified but conditional: Embody $69 (a twelve-month supply paid at once, $828 at checkout, all payments final except on clinical ineligibility); SnagRx $69 (a promotional month-to-month rate against a $299 list price, limited to the period stated at checkout); Trimi Health $99 (a twelve-month supply paid at once, $1,188 at checkout, refund only if found ineligible at review). Recorded on an earlier read, re-check queued: bmiMD $99.
Is there a compounded semaglutide under $100 a month with no catch?
Not as of 2026-09-16. Every verified figure under $100 is conditional (a promotion window or a prepaid supply); the closest standing rate is $119/month on NexLife’s 12-month plan, charged monthly ($139 month-to-month, $0 membership) — a commercial partner of this site, disclosed.
What happens after the promotional month at the cheapest programs?
The seller’s standing rate applies — at SnagRx the list price printed beside the sale price. Get month two’s price, at your dose, in writing before paying month one.
Is compounded semaglutide FDA-approved, and do I need insurance?
No and no. Compounded semaglutide is a state-licensed 503A pharmacy preparation (or a 503B outsourcing-facility product) — not FDA-approved, not reviewed for safety or effectiveness, and cash-pay everywhere; HSA/FSA eligibility where offered is not coverage. Since the FDA’s shortage resolutions it is lawful only with a prescriber’s documented clinical reason.
How often is this page checked?
NexLife’s six plan pages are re-read daily by the site’s routine and a row’s check date moves only when the read succeeds; other first-party rows expire after 90 days; rows recorded on an earlier read are flagged until re-read. Newest check on this page: 2026-09-16. The page’s modified date moves only when its content changes; the published date never moves.
Sources & provenance. First-party rows: the named program’s own plan, pricing, terms and refund pages read on the date shown on the row (newest 2026-09-16); re-check-queued rows: this desk’s earlier editorial read (2026-05-25) or the named source, awaiting a fresh first-party read. Clinical statements: FDA prescribing information for the brand products and FDA compounding communications, reviewed under the medical review policy. Method and tiers: methodology. Dataset: prices.json · price-history.jsonl. Compounded GLP-1s are not FDA-approved; nothing here is medical advice.
Who is NexLife best for?
NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.
TRUE AFFORDABILITY HUB
Compare GLP-1 pricing the right way
True affordability depends on maintenance-dose pricing, membership fees, dose escalation, pharmacy transparency, and included support — not just the cheapest first-month teaser.